Waystar heads into its third-quarter report with a stock that has run well ahead of its fundamentals' most recent trajectory. Shares have climbed more than 34% since the last report, while the S&P 500 gained about 3%. That rally came even though the company's net revenue retention fell for a fourth straight quarter and organic growth cooled noticeably. The question for this report is whether the market was right to look past that deceleration, or whether it simply priced in a recovery that has not yet arrived.
The Street is looking for non-GAAP earnings of $0.41 per share on revenue of about $324.1 million, which would be roughly 20.6% revenue growth from the year-ago $268.7 million. That headline growth rate flatters the underlying business. Last quarter, organic growth was just 7%, or about 10% on a normalized basis, so much of the reported expansion reflects acquired revenue rather than core momentum. The earnings bar is more demanding than it first appears. Waystar earned $0.32 in the second quarter and $0.32 in the same quarter a year ago, so consensus implies a sizable step up on only modestly higher revenue. The Earnings Whisper of $0.42 sits a penny above consensus, a small difference but one that suggests the informal bar leans slightly higher.
Management's full-year outlook frames how much room exists. Waystar nudged its 2026 range to $1.61 to $1.70 per share on revenue of $1.276 billion to $1.294 billion, and lifted adjusted EBITDA guidance to a $540 million midpoint. Consensus of $1.67 sits in the upper half of the earnings range, while the $1.28 billion revenue estimate sits in the lower half. That split tells the story: analysts trust Waystar's cost discipline more than its top line. Second-quarter adjusted EBITDA margin ran at 43%, ahead of the 42% full-year target, and another quarter at that level would support the earnings view even if revenue merely meets expectations. The company has beaten nine quarters in a row, but its raises have been incremental, so a tenth beat accompanied by only a token raise may not be enough for a stock priced this richly.
The operational evidence matters more than the headline numbers. Net revenue retention slid from 113% to 108%, now at the bottom of the company's historical 108% to 110% band, as tailwinds from elevated patient utilization and earlier industry disruption faded. Volume-based revenue grew only 3% last quarter as utilization drifted back toward its long-term 1% to 2% pace. If retention holds at 108% or ticks up, it would validate management's argument that the slowdown is a comparison issue rather than a demand problem. Another step below the range would challenge that narrative directly, especially with coverage pressure from ACA exchange roll-offs and Medicaid declines still in the background.
On the offense side, management pointed to a fourth consecutive quarter with a double-digit count of deals above $1 million in annual contract value, more than $6 million in cross-sell bookings for iodine capabilities, and early traction for new AI products, including next-generation anomaly detection and an automated payer recoupment tool. Continued growth in clients generating over $100,000 annually, which reached 1,453 last quarter, would show that these bookings are converting into larger relationships. Free cash flow is also worth watching after conversion fell to 47% on tax timing while capitalized software roughly doubled. A rebound would ease worries that AI spending is eating into cash generation, and the first report under a new CFO will be judged on how clearly that tradeoff is explained.
Sentiment has softened from 58.7% bearish to 52.8% bearish, so skepticism is fading but has not disappeared. The stock trades well above its 200-day moving average near $24 and sits within about 1.5% of its post-earnings high of $29.25, effectively testing a breakout. That leaves little cushion. For the rally to hold, Waystar needs to show that retention and organic growth have stabilized, not just that margins can carry another quarter.